ColoSense
Geneoscopy, Inc. · Decision date Oct 24, 2025
What did the FDA decide?
FDA records P230001/S011 as a supplement to PMA P230001, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 24, 2025.
FDA approval order statement
approval for modifying the concentration of a reagent used in the manufacturing process of QC materials and the qualification of an alternate reagent supplier
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Oct 24, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230001/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- Decision code
- OK30
- Decision date
- Oct 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230001. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230001 · Original PMA
ColoSense
P230001/S010 · Related supplement
ColoSense
P230001/S009 · Related supplement
ColoSense
P230001/S011 received
Application receipt date recorded by FDA.
P230001/S011 · FDA decision
30-Day Notice
P230001/S012 · Related supplement
ColoSense
P230001/S014 · Related supplement
ColoSense
Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ColoSenseP230001 | Geneoscopy, Inc. | PMA approval | May 3, 2024 | FDA |
ColoSenseP230001/S010 | Geneoscopy, Inc. | PMA supplement | Aug 14, 2025 | FDA |
ColoSenseP230001/S009 | Geneoscopy, Inc. | PMA supplement | Sep 15, 2025 | FDA |
ColoSenseP230001/S012 | Geneoscopy, Inc. | PMA supplement | Aug 27, 2026 | FDA |
ColoSenseP230001/S014 | Geneoscopy, Inc. | PMA supplement | Sep 8, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Geneoscopy, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2220 Welsch Industrial Ct., St. Louis, MO, 63146
Sources and methodology
- Original FDA record: P230001/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


